Get the Stockscreener App
18.55
1.01%
-0.19
After Hours:
18.55
Schrodinger Inc stock is traded at $18.55, with a volume of 487.61K.
It is down -1.01% in the last 24 hours and down -11.79% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$18.74
Open:
$18.7
24h Volume:
487.61K
Relative Volume:
0.76
Market Cap:
$1.35B
Revenue:
$188.48M
Net Income/Loss:
$-143.14M
P/E Ratio:
33.12
EPS:
0.56
Net Cash Flow:
$-158.83M
1W Performance:
-2.16%
1M Performance:
-11.79%
6M Performance:
-31.30%
1Y Performance:
-34.38%
1-Day Range:
$18.54
$19.02
1-Week Range:
$18.39
$19.42
52-Week Range:
$18.02
$38.00
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues - Simply Wall St
Schrodinger discovers EGFR mutant inhibitors - BioWorld Online
Goldman Sachs holds neutral on Schrodinger stock By Investing.com - Investing.com Canada
Goldman Sachs holds neutral on Schrodinger stock - Investing.com
(SDGR) Trading Advice - Stock Traders Daily
Rubric Capital Management LP Buys 2,131,724 Shares of Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrodinger Inc (SDGR) Shares Gap Down to $20.02 on Sep 20 - GuruFocus.com
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm - The Malaysian Reserve
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm - PR Newswire
Schroders Capital Buys Back and Cancels Shares - TipRanks
Schwab 5-10 Year Corporate Bond ETF (NYSEARCA:SCHI) Hits New 12-Month High at $46.61 - Defense World
Commonwealth Equity Services LLC Increases Position in Schwab 5-10 Year Corporate Bond ETF (NYSEARCA:SCHI) - Defense World
Noteworthy Wednesday Option Activity: DUOL, ALGM, SPHR - Nasdaq
Stryker Stock Declines Despite Completion Of Care.ai Acquisition - Barchart
Schroder Income Growth (LON:SCF) Sets New 1-Year High at $305.00 - Defense World
Transaction in Own Shares - ShareCast
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Schrödinger, Inc. (SDGR): A Bull Case Theory - Insider Monkey
Schrödinger, Inc. (SDGR): A Bull Case Theory - Yahoo Finance
Schrodinger Inc’s results are impressive - US Post News
Quest Partners LLC Raises Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schbang acquires Addikt to boost global influence and expand into European market - The Financial Express
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Schbang Strengthens Global Footprint, Acquires Amsterdam-based Design Agency 'Addikt' - Marketing Strategy, Brands ...
Schbang strengthens international footprint with acquisition of Addikt, eyes European expansion - Campaign India
Schbang acquires Dutch design agency Addikt to form combined entity with turnover Rs 300 cr - Storyboard18
A History of Outperforming Analyst Forecasts and Beating the Odds: Schrodinger Inc (SDGR) - SETE News
Love the SCHD ETF? USA is a great 10% yielding alternative - Invezz
Gaining Ground: Schrodinger Inc (SDGR) Closes Higher at 20.73, Up 0.68 - The Dwinnex
Analyst bullish on Schrodinger stock, cites unique physics-based computation methods - Investing.com
Schrodinger Inc. streamlines agreements with Columbia University - Investing.com India
Analyst bullish on Schrodinger stock, cites unique physics-based computation methods - Investing.com India
Schrodinger Inc. streamlines agreements with Columbia University - Investing.com
STANCHART Sets Up New Banking Team for Large Cross-border Deals: Report - AASTOCKS.com
Schrodinger Inc. streamlines agreements with Columbia University By Investing.com - Investing.com UK
When (SDGR) Moves Investors should Listen - Stock Traders Daily
Schrödinger, Inc. (NASDAQ:SDGR) Stock Position Lifted by Bank of New York Mellon Corp - MarketBeat
Pier 88 Investment Partners LLC Buys 26,750 Shares of Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Foundations Investment Advisors LLC Buys Shares of 45,399 Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Top 5 AI & Digital Biotech Companies (September 2024) - Securities.io
Schrödinger (NASDAQ:SDGR) Shares Up 7% - MarketBeat
Schrödinger, Inc. (SDGR): Among The Best Medical AI Companies - Insider Monkey
Schrödinger, Inc. (SDGR): Among The Best Medical AI Companies - Yahoo Finance
7 Mighty Medical Stocks That Will Keep Getting Stronger in 2024 - MarketBeat
Schrödinger, Inc. (NASDAQ:SDGR) Holdings Decreased by Baillie Gifford & Co. - MarketBeat
Schrödinger (NASDAQ:SDGR) Price Target Lowered to $30.00 at Morgan Stanley - Defense World
Morgan Stanley cuts Schrodinger shares target as drug discovery projections decrease - Investing.com India
Morgan Stanley cuts Schrodinger shares target as drug discovery projections decrease - Investing.com
Morgan Stanley cuts Schrodinger shares target as drug discovery projections decrease - Investing.com Canada
Morgan Stanley cuts Schrodinger shares target as drug discovery projections decrease By Investing.com - Investing.com South Africa
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):